Ras-mediated modulation of pyruvate dehydrogenase activity regulates mitochondrial reserve capacity and contributes to glioblastoma tumorigenesis

Neuro-Oncology

Volumn 17, Issue 9, 2015, Pages 1220-1230

  Prabhu, Antony ^a   Sarcar, Bhaswati ^a   Miller, C Ryan ^b   Kim, Sung Hak ^c   Nakano, Ichiro ^c   Forsyth, Peter ^a   Chinnaiyan, Prakash ^a,d  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d OAKLAND UNIVERSITY WILLIAM BEAUMONT SCHOOL OF MEDICINE   (United States)

Author keywords

glioblastoma; pyruvate dehydrogenase; Ras; spare respiratory capacity; tumor metabolism

Indexed keywords

PYRUVATE DEHYDROGENASE; PYRUVATE DEHYDROGENASE PHOSPHATASE; PYRUVATE DEHYDROGENASE PHOSPHATASE 1; RAS PROTEIN; UNCLASSIFIED DRUG; PYRUVATE DEHYDROGENASE COMPLEX;

AEROBIC METABOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOENERGY; CANCER STEM CELL; CARCINOGENESIS; CELLULAR PARAMETERS; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REPRESSION; GLIOBLASTOMA; GLYCOLYSIS; HUMAN; HUMAN CELL; IN VIVO STUDY; INTRACELLULAR SIGNALING; MITOCHONDRIAL RESERVE CAPACITY; MITOCHONDRIAL RESPIRATION; MOUSE MODEL; NONHUMAN; OXYGEN CONSUMPTION; PHENOTYPE; PROTEIN EXPRESSION; REGULATORY MECHANISM; STABLE EXPRESSION; ANIMAL; BRAIN TUMOR; ENERGY METABOLISM; ENZYMOLOGY; METABOLISM; MITOCHONDRION; MOUSE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; ENERGY METABOLISM; GLIOBLASTOMA; HUMANS; MICE; MITOCHONDRIA; PYRUVATE DEHYDROGENASE (LIPOAMIDE)-PHOSPHATASE; PYRUVATE DEHYDROGENASE COMPLEX; RAS PROTEINS; SIGNAL TRANSDUCTION;

EID: 84940765083     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nou369     Document Type: Article

References (36)

1. Warburg O. On respiratory impairment in cancer cells. Science. 1956;124(3215):269-270.
2. Warburg O, Posener K, Negelein E. Uber den Stoffwechsel der Carcinomzelle. Biochem Zeitschr. 1924;152:309-344.
3. Marin-Valencia I, Yang C, Mashimo T, et al. Analysis of tumor metabolism reveals mitochondrial glucose oxidation in genetically diverse human glioblastomas in the mouse brain in vivo. Cell Metab. 2012;15(6):827-837.
4. Moreno-Sanchez R, Rodriguez-Enriquez S, Marin-Hernandez A, Saavedra E Energy metabolism in tumor cells. FEBS J. 2007; 274(6):1393-1418.
5. Chinnaiyan P, Kensicki E, Bloom G, et al. The metabolomic signature of malignant glioma reflects accelerated anabolic metabolism. Cancer Res. 2012;72(22):5878-5888.
6. Locasale JW, Grassian AR, Melman T, et al. Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet. 2011;43(9):869-874.
7. Possemato R, Marks KM, Shaul YD, et al. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature. 2011;476(7360):346-350.
8. Ying H, Kimmelman AC, Lyssiotis CA, et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell. 2012;149(3):656-670.
9. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996.
10. TCGA. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455(7216): 1061-1068.
11. Chakravarti A, Zhai G, Suzuki Y, et al. The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J Clin Oncol. 2004;22(10):1926-1933.
12. Lopez-Gines C, Gil-Benso R, Benito R, et al. The activation of ERK1/2 MAP kinases in glioblastoma pathobiology and its relationship with EGFR amplification. Neuropathology. 2008;28(5):507-515.
13. Nicoletti NF, Erig TC, Zanin RF, et al. Mechanisms involved in kinin-induced glioma cells proliferation: the role of ERK1/2 and PI3K/Akt pathways. J Neurooncol. 2014;120(2):235-244.
14. Prabhu A, Sarcar B, Kahali S, et al. Cysteine catabolism: a novel metabolic pathway contributing to glioblastoma growth. Cancer Res. 2014;74(3):787-796.
15. Choi SW, Gerencser AA, Nicholls DG. Bioenergetic analysis of isolated cerebrocortical nerve terminals on a microgram scale: spare respiratory capacity and stochastic mitochondrial failure. J Neurochem. 2009;109(4):1179-1191.
16. Vlashi E, Lagadec C, Vergnes L, et al. Metabolic state of glioma stem cells and nontumorigenic cells. Proc Natl Acad Sci USA. 2011;108(38):16062-16067.
17. Pollard SM, Yoshikawa K, Clarke ID, et al. Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell. 2009;4(6):568-580.
18. Prabhu A, Sarcar B, Kahali S, et al. Targeting the unfolded protein response in glioblastoma cells with the fusion protein EGF-SubA. PLoS One. 2012;7(12):e52265.
19. Vitucci M, Karpinich NO, Bash RE, et al. Cooperativity between MAPK and PI3K signaling activation is required for glioblastoma pathogenesis. Neuro Oncol. 2013;15(10):1317-1329.
20. Mao P, Joshi K, Li J, et al. Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3. Proc Natl Acad Sci USA. 2013; 110(21):8644-8649.
21. Song Y, Zhang Q, Kutlu B, et al. Evolutionary etiology of high-grade astrocytomas. Proc Natl Acad Sci USA. 2013;110(44): 17933-17938.
22. Guha A, Feldkamp MM, Lau N, et al. Proliferation of human malignant astrocytomas is dependent on Ras activation. Oncogene. 1997;15(23):2755-2765.
23. Hill BG, Dranka BP, Zou L, et al. Importance of the bioenergetic reserve capacity in response to cardiomyocyte stress induced by 4-hydroxynonenal. Biochem J. 2009;424(1):99-107.
24. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003;3(1):11-22.
25. Michelakis ED, Sutendra G, Dromparis P, et al. Metabolic modulation of glioblastoma with dichloroacetate. Sci Transl Med. 2010;2(31):31ra34.
26. Sandulache VC, Skinner HD, Ow TJ, et al. Individualizing antimetabolic treatment strategies for head and neck squamous cell carcinoma based on TP53 mutational status. Cancer. 2012;118(3):711-721.
27. Anso E, Mullen A, Felsher D, et al. Metabolic changes in cancer cells upon suppression of MYC. Cancer Metab. 2013;1(1):7.
28. Jain RK. Molecular regulation of vessel maturation. Nat Med. 2003; 9(6):685-693.
29. Vartanian A, Singh SK, Agnihotri S, et al. GBM's multifaceted landscape: highlighting regional and microenvironmental heterogeneity. Neuro Oncol. 2014;16(9):1167-1175.
30. Dewhirst MW. Intermittent hypoxia furthers the rationale for hypoxia-inducible factor-1 targeting. Cancer Res. 2007;67(3): 854-855.
31. Brand KA, Hermfisse U. Aerobic glycolysis by proliferating cells: a protective strategy against reactive oxygen species. FASEB J. 1997;11(5):388-395.
32. Sohal RS, Weindruch R. Oxidative stress, caloric restriction, and aging. Science. 1996;273(5271):59-63.
33. Chiaradonna F, Sacco E, Manzoni R, et al. Ras-dependent carbon metabolism and transformation in mouse fibroblasts. Oncogene. 2006;25(39):5391-5404.
34. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer. 2011;11(2):85-95.
35. Logue JS, Morrison DK. Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy. Genes Dev. 2012;26(7):641-650.
36. Kaplon J, Zheng L, Meissl K, et al. A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence. Nature. 2013;498(7452):109-112.